Q1 2024 EPS Estimates for Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Reduced by Analyst

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) – Equities researchers at HC Wainwright reduced their Q1 2024 earnings estimates for shares of Marinus Pharmaceuticals in a research note issued on Tuesday, May 7th. HC Wainwright analyst D. Tsao now expects that the biopharmaceutical company will post earnings of ($0.70) per share for the quarter, down from their previous estimate of ($0.69). HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Marinus Pharmaceuticals’ current full-year earnings is ($2.23) per share. HC Wainwright also issued estimates for Marinus Pharmaceuticals’ Q2 2024 earnings at ($0.52) EPS, Q3 2024 earnings at ($0.54) EPS, Q4 2024 earnings at ($0.39) EPS, FY2024 earnings at ($2.15) EPS, Q1 2025 earnings at ($0.47) EPS, Q2 2025 earnings at ($0.38) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.02) EPS, FY2025 earnings at ($1.18) EPS, FY2026 earnings at ($0.82) EPS, FY2027 earnings at $0.91 EPS and FY2028 earnings at $2.86 EPS.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its quarterly earnings data on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.10). The company had revenue of $7.19 million for the quarter, compared to analysts’ expectations of $7.78 million. Marinus Pharmaceuticals had a negative net margin of 456.31% and a negative return on equity of 269.75%. During the same quarter in the previous year, the business posted ($0.76) EPS.

A number of other analysts also recently issued reports on MRNS. Robert W. Baird reissued a “neutral” rating on shares of Marinus Pharmaceuticals in a report on Tuesday, April 16th. Royal Bank of Canada restated a “sector perform” rating and set a $3.00 target price (down from $24.00) on shares of Marinus Pharmaceuticals in a research report on Monday, April 15th. StockNews.com downgraded Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, March 6th. Oppenheimer restated a “market perform” rating and issued a $9.00 price objective on shares of Marinus Pharmaceuticals in a research report on Thursday, March 7th. Finally, Truist Financial decreased their target price on Marinus Pharmaceuticals from $25.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, April 17th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $13.79.

Marinus Pharmaceuticals Trading Down 8.9 %

Shares of NASDAQ:MRNS opened at $1.43 on Thursday. The company has a market capitalization of $78.55 million, a PE ratio of -0.54 and a beta of 1.14. Marinus Pharmaceuticals has a 12-month low of $1.11 and a 12-month high of $11.26. The business has a 50 day moving average of $6.18 and a two-hundred day moving average of $7.84. The company has a current ratio of 4.07, a quick ratio of 4.01 and a debt-to-equity ratio of 5.68.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. lifted its stake in shares of Marinus Pharmaceuticals by 383.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,307 shares of the biopharmaceutical company’s stock valued at $69,000 after purchasing an additional 5,003 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Marinus Pharmaceuticals in the 4th quarter worth approximately $134,000. Sherbrooke Park Advisers LLC purchased a new position in shares of Marinus Pharmaceuticals during the 3rd quarter worth approximately $141,000. Acuta Capital Partners LLC purchased a new position in shares of Marinus Pharmaceuticals during the 3rd quarter worth approximately $157,000. Finally, Trexquant Investment LP acquired a new stake in Marinus Pharmaceuticals in the 4th quarter valued at approximately $553,000. 98.80% of the stock is currently owned by hedge funds and other institutional investors.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.